



Advancing brain health. Transforming lives.

Lundbeck is one of the few pharmaceutical companies dedicated exclusively to brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

A portrait of a young woman, Juliana, with dark hair and bangs, looking slightly upwards and to the right. She is wearing a green t-shirt and a black and grey safety harness. The background is a blurred indoor setting with bookshelves.

Juliana,
living with Rett syndrome and
diagnosed with a developmental
and epileptic encephalopathy (DEE)

Brain disorders affect a significant proportion of the world's population, with consequences felt by individuals, families and society as a whole.¹

As our understanding of the brain continues to evolve, we are committed to advancing brain health by exploring new possibilities for treatment with curiosity and purpose.

3.4 billion

People worldwide live with a neurological disorder - one of the leading causes of disability and the second-leading cause of death.¹

1. WHO, Global status report on neurology 2025

Mirza,
caregiver of a person living
with Alzheimer's disease



27.8M

Patients reached
in 2025

~20%

Of annual revenue
reinvested in research
and development

+80

Countries where
our products are
registered

Focused exclusively on brain diseases

Lundbeck is one of the few pharmaceutical companies in the world focused exclusively on brain diseases. This specialization sets us apart.

As a focused innovator, we develop research and development programs that address some of the most complex challenges in neuroscience. We work to create transformative medicines for people who have few or no treatment options, building on our strong heritage in psychiatry and neurology while expanding into neuro-specialty and neuro-rare diseases.

We are committed to reducing stigma and advancing health equity. At the same time, we strive to create long-term value for shareholders by making a positive contribution to patients, their families and society.

The complexity of brain diseases demands collaboration. From early-stage science through to commercialization, partnerships are central to our strategy and our ambition to lead in brain health. Lundbeck has more than 5,000 employees across more than 20 countries.

Underpinned by unique ownership

The Lundbeck Foundation is Lundbeck's largest shareholder, owning approximately 70% of the company. Through its support for research and The Brain Prize, the Foundation helps advance neuroscience and reinforces Lundbeck's long-term perspective.

"Our ambition is to improve brain health for the benefit of patients, people and society."



Learn more about Lundbeck

Discover our science, strategy and partnerships at www.lundbeck.com, and connect with us on LinkedIn.

©2026 Lundbeck. All rights reserved.

